iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Lupin Bioresearch centre successfully passes USFDA Inspection without observations

14 Mar 2023 , 02:50 AM

Lupin Limited, a leading global pharmaceutical company, reported today that the Bioresearch Centre situated in Pune, India, underwent inspection USFDA. The inspection did not result in any adverse observation. 

Lupin Bioresearch Centre performs various studies such as BA/BE, PK/PD, In-vitro BE, and biosimilar assessments. The inspection concluded without any findings or remarks.

Nilesh Gupta, the Managing Director of Lupin, expressed satisfaction in declaring that the Lupin Bioresearch Centre had passed its seventh consecutive onsite assessment, thereby reiterating Lupin’s dedication to ensuring patient safety and maintaining the highest standards of quality and compliance.

Recently, Lupin also announced that USFDA concluded a pre-approval and GMP inspection at its API manufacturing facility located in Visakhapatnam (Vizag), India with no observations.

At around 2.51 PM, Lupin was trading at Rs656.90, against the previous close of Rs654.30 on NSE. The counter touched an intraday high and low of Rs668.90 and Rs652.20 respectively.

For feedback and suggestions, write to us at editorial@iifl.com

explored-media

Related Tags

  • Lupin
  • Lupin News
  • Lupin Stock
  • Lupin Updates
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.